Blincyto (blinatumomab) / Astellas, Amgen, BeOne Medicines - LARVOL DELTA

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial (ASH 2024) - P3 | "Eligible pts received the CALGB 10403 regimen modified to omit extended induction, include dexamethasone as opposed to prednisone as steroid backbone, cap the pegaspargase dose to 3750 units, and adding rituximab for pts with CD20 expression (> 20%). INO may still be efficacious if late toxicity can be mitigated. A pilot study is planned that will decrease INO dose, add 2 cycles of blinatumomab and strict infectious prophylaxis guidelines."

Clinical • P3 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Septic Shock • ABL1 • CD20 • CD22

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial (ASH 2025) - P1 | "Due to distinct mechanisms of action and non-overlapping toxicities, we hypothesized that adding VEN to INO would be safe and effective. This investigator-sponsored phase I study (NCT05016947) enrolled pts ≥18 years with CD22+ (≥20% ofblasts) R/R ALL (≥5% bone marrow [BM] blasts) or lymphoblastic lymphoma (LBL, BM <5% blasts).Philadelphia chromosome-negative (Ph-) pts had received ≥1 line of therapy; Ph+ pts were ponatinib(PON)-refractory or ineligible...Dexamethasone (10 mg/m2) was given during Lead-In and D1-4 of C1 Induction...BH3 profiling showed that ptsMRD- by C2 had lower pre-treatment mitochondrial apoptotic priming.Of the 21 CR patients, 1 pt (KMT2Ar) progressed during C2, and the remaining 20 pts (95.2%) wereconsolidated with blinatumomab (n=9, 42.9%), SCT (n=14, 66.7%, 6 after blinatumomab), DLI (n=1), XRT(n=1), or POMP (n=1)... VEN can be safely added to INO in pts with R/R CD22+ ALL/LBL including Ph+ ALL, with a very high anddurable rate of MRD- CR...."

P1 data • CNS Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Hepatology • Lymphoblastic Lymphoma • Lymphoma • Neutropenia • Thrombocytopenia • KMT2A

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients (ASH 2025) - "Compared to the GIMEMA LAL2116 trial, anincrease in MRD negativity and less relapses were observed. A chemo-free approach should be the newstandard for adult Ph+ ALL."

Clinical • IO biomarker • P3 data • Acute Lymphocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myocardial Infarction • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • ABL1 • IKZF1

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission (ASH 2025) - P1 | "2022), administered following LD with fludarabine and cyclophosphamide.Pts are followed for toxicity and minimal residual disease (MRD) relapse by flow cytometry (FC) andclonoSEQ (if feasible) every 3 months for 2 years...Six pts had Ph+, 5 hadnot otherwise specified (NOS), 2 had hypodiploidy/TP53m, 2 had CRLF2-rearranged Ph-like, 1 each hadKMT2Ar, EP300::ZNF384, and TCF3::PBX1; 15 (83%) and 2 (11%) pts received blinatumomab andinotuzumab as part of initial therapy, respectively...A second pt (75 yrs old; received induction with hyper CVAD +inotuzumab) developed therapy-related myelodysplastic syndrome 18 months post CAR-T... The use of CAR-T in older adults with B-ALL in MRD- CR1 is safe, with the only encounteredtoxicity of G1 CRS, which was manageable. CAR-T cells expanded in the blood and CSF despite the lowantigen setting. We observed preliminary durable MRD- CR with preserved function and cognition on day100 post CAR-T."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • CRLF2 • EP300 • KMT2A • PBX1 • TCF3 • ZNF384

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (ASH 2025) - "Tyrosine kinase inhibitor (TKI) + blinatumomab regimenshave demonstrated high MR4 rates and favorable overall survival (OS); however, these regimens includeup to 5 courses of blinatumomab which is a continuous 28-day infusion (Kantarjian et al, JCO 2024; Foa etal, JCO 2024)...Eligibilitycriteria includes newly diagnosed Ph+ ALL, age ≥ 18, ECOG ≤2, CD22+ on ≥20% blasts, and no centralnervous system (CNS) disease.Schema 1 was as follows; Course (C) 1 was (28 days) dasatinib (DAS) 140mg daily, dexamethasone (dex)10mg/m2 D1-7 & D15-21, and InO 0.8mg/m2 D8, 0.5mg/m2 D15 and D22...If MR4 was not achieved by end of C2 (EOC2), DAS was switched to ponatinib(PON)...TKI + InO-based therapy for newly diagnosed pts with Ph+ ALL has an MR3+ rate of 81% within 2 coursesand 100% of pts achieved MR4 and/or NGS MRD- disease by EOC3. No cases of VOD were seen withSchema 2. Given the excellent rates of MR3+ with limited cycles of InO, further development of thisinduction approach is..."

Clinical • P2 data • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Pulmonary Disease • Respiratory Diseases • Septic Shock • IKZF1

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia (ASH 2025) - P2 | "Patients received huCART19 at a dose of 5x106 CAR T cells/kg (maximum 2.5x108) afterlymphodepletion (LD) with fludarabine and cyclophosphamide...Prior therapy included HSCT in 21%, blinatumomab in 21% and inotuzumab in 15%.The CAR-naïve cohort (n=52) included 25 with first early BM relapse within 36m of diagnosis (12 25% blasts, 25/52 (48%) <0.01%...There was 1 death prior to day 28, due to gastrointestinal hemorrhageon day 2 in the setting of progressive ALL and Gr 2 CRS. CAR neurotoxicity was reported in 14/52 (27%, 2Gr 3, 2 Gr 4) CAR-naïve patients and 7/48 (15%, 1 Gr 3, 1 Gr 4) CAR-exposed, with 1 case of Gr 3 cerebraledema, fully recovered, and 1 case of ongoing myelopathy.ConclusionsHuCART19 produced durable remissions in high risk r/r B-ALL and demonstrated efficacy as salvagetherapy for those with poor response to prior CAR therapy, comparing favorably to historical outcomes inthis extremely high risk group."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ASH 2025) - P1/2 | "Introduction: MK-1045 (CN201) is a humanized bispecific IgG4 CD19xCD3 T-cell engager that has shownencouraging safety, tolerability, and preliminary efficacy in participants with relapsed or refractory (R/R)B-cell acute lymphoblastic leukemia (B-ALL) (Wang et al...Among participants withprior exposure to blinatumomab or CAR T-cell therapy who had received a target dose ≥60 mg, 5 of 5participants achieved CR/CRi/CRh and 4 achieved MRD negativity... The safety profile of MK-1045 in adult participants with R/R B-ALL has been generallymanageable with dose modifications and standard medical care. MK-1045 has shown encouraging singleagent antitumor activity in adult participants with R/R B-ALL, achieving a CR/CRi/CRh rate of 92% at the2/20/90 mg dose level."

Clinical • P1/2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701) (ASH 2025) - P2 | "Based upon retrospectivedata showing low rates of relapse, we hypothesized that patients with negative pre-HCT MRD by next-generation-sequencing of IgH B-cell receptor rearrangements (NGS-MRD) could achieve 2-year EFSexceeding 75% with a non-TBI regimen, an outcome comparable to those receiving TBI-based regimens. The Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) conducted a phase IIprospective trial at 45 Centers in North America (ONC1701 EndRAD: NCT03509961) between 2018 and2025 to evaluate outcomes of myeloablative non-TBI conditioning regimens for allogeneic HCT in B-ALLpatients at lower risk for relapse defined by absence of NGS-MRD (Clonoseq) of B-cell receptorrearrangements (BCR) just prior to HCT...Mismatched related/haploidentical grafts received post-transplant cyclophosphamide orTCRαβ/CD19 depletion according to institutional preference...Of patientsenrolled, 33% were White/Non-Hispanic, 37% Hispanic, 12% Black or African American, and..."

Biomarker • Clinical • IO biomarker • Minimal residual disease • Next-generation sequencing • Residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. (ASH 2025) - P1/2 | "Leukapheresis could be followed by further chemo-immunotherapy and then standard lymphodepletion (LD) with fludarabine-cyclophosphamide beforebrexucel infusion...Adverse events included cytokine release syndrome (CRS) in 8 (57%) pts (all grade 1); 3 pts neededsingle dose tocilizumab... From Dec 2024-July 31 2025, 28 pts have had leukapheresis,18 pts were infused and 14 pts with afollow-up (FU) >1 month post brexucel infusion were included in this report. The median age of theinfused pts was 35 years (range 19-77), and 5 pts (36%) were ³60 years of age. Ten pts (71%) receivedbrexcuel as FL consolidation therapy for adverse genomics, 3 FL pts (21%) had persistent (n=2)/recurrent(n=1) MRD, and 1 (7%) pt had R/R ALL."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • KMT2A • TP53

Short-duration blinatumomab for residual disease eradication as a bridge to transplant in B-ALL: Pediatric and adult outcomes in a resource-limited context (ASH 2025) - P=N/A, P2 | "Conditioning for children was melphalan-based plus 2 Gy total body irradiation (TBI) in haploidentical grafts; for adults 12 Gy total marrow andlymphoid irradiation (TMLI) (NCT06209190). Graft-versus-host disease (GVHD) prophylaxis was post-transplant cyclophosphamide, tacrolimus and mycophenolate...OS at 24 months was 63%, median NR (95% CI 22.97-43.15), EFS at 24 months was 55%, with amedian of 42 months (95% CI 4.39-79.60%). N=2 died after HCT in remission due to pneumonia and athromboembolic event.ConclusionsA short-course of blinatumomab is effective, demonstrating that it can be an adaptable alternative in low-and middle-income countries as a bridge to HCT for R/R patients in CR with detectable MRD."

Clinical • Residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Pneumonia • Respiratory Diseases • Transplantation

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) (ASH 2025) - P1/2 | "Sixteen pts (46%) were previously treated with blinatumomaband 13 pts (37%) with inotuzumab...CRS management includedtocilizumab (70%), siltuximab (10%), corticosteroids (40%), tocilizumab plus corticosteroids (37%), andanakinra (7%)...Seven pts received supportive measures for ICANS,including dexamethasone (5 pts, 71%) and anakinra (3 pts, 43%)... Phase 1 results with long follow-up suggest rapcabtagene autoleucel is active with highcellular expansion, durable efficacy for DL2–DL4, and a manageable safety profile in adult pts with r/r B-ALL. DL3—at which 92% of pts achieved BOR of CR/CRi by 3 mo, with median DOR not reached after 22mo median follow-up—exhibited an acceptable balance of safety, efficacy, and cellular expansion."

Clinical • P1 data • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Neutropenia • Rare Diseases

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease (ASH 2025) - P1 | "Introduction: Immunotherapies targeting CD19, such as blinatumomab and CAR T cells, have shownremarkable efficacy in relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL)...DL-1 (de-escalation) and DL1 (starting dose) consist ininfusion with 20M and 50M CAR T cells, respectively, after lymphodepletion (LD) with cyclophosphamideonly... BAFFR-CAR T cell therapy demonstrated an excellent initial safety profile. Following LD withcyclophosphamide and fludarabine, the 50M dose demonstrated robust expansion and promisingactivity in heavily pretreated pts with r/r B-ALL who had failed prior CD19-targeted therapies and hadlimited treatment options. Treatment successfully transitioned pts to potentially curative transplant."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • IL6

Short-Duration Blinatumomab for Residual Disease Eradication As a Bridge to Transplant in B-ALL: Pediatric and Adult Outcomes in a Resource-Limited Context (TCT-ASTCT-CIBMTR 2026) - P=N/A, P2 | "Conditioning for children was melphalan-based plus 2 Gy total body irradiation (TBI) in haploidentical grafts; for adults 12 Gy total marrow and lymphoid irradiation (TMLI) (NCT06209190). Graft-versus-host disease (GVHD) prophylaxis was post-transplant cyclophosphamide, tacrolimus and mycophenolate...Conclusionn A short-course of blinatumomab as a bridge to HCT is an effective, adaptable strategy in low- and middle- income countries for ALL RR patients in CR with detectable MRD. Short course blinatumomab is effective in low burden disease Shorter cycles of blinatumomab can enhance the acces Short course blinatumomab is an adaptable therapy for low and middle income contries"

Clinical • Residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Pneumonia • Respiratory Diseases • Transplantation

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. (PubMed, J Hematol Oncol) - P2 | "WBC ≥ 70 × 109/L is a high-risk feature in patients with Ph + ALL receiving frontline blinatumomab and ponatinib and may supersede the prognostic importance of baseline molecular features. Alternative frontline treatment strategies may be needed for these patients to reduce the risk of relapse and improve long-term outcomes."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD19 • IKZF1 • VPREB1

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial (ASH 2025) - P3 | "We provide a comprehensive landscape of genomic alterations in adult B-ALL and identify anew group characterized by deregulation of CEBPA/CEBPB (CEBPalt). We also provide insights into theefficacy of blinatumomab in different molecular subgroups of adult B-ALL."

Clinical • IO biomarker • P3 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • T Acute Lymphoblastic Leukemia • ABL1 • ASXL1 • BCL2 • CEBPA • CEBPB • CRLF2 • DNMT3A • KMT2A • PBX1 • TCF3 • TET2 • TP53 • ZEB2 • ZNF384

Targeted therapies in pediatric B-Cell acute lymphoblastic leukemia: mechanisms, efficacy, and future directions. (PubMed, Front Pharmacol) - "CD19-directed CAR-T-cell therapy and bispecific antibodies (e.g., blinatumomab) have demonstrated high remission rates in early-phase clinical trials...Their integration into standard protocols, especially for high-risk and relapsed patients, is crucial to enhancing long-term outcomes. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251110522, identifier CRD420251110522."

Journal • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics • ABL1 • BCR

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. (PubMed, Lancet Haematol) - P1/2 | "Treatment with subcutaneous blinatumomab at the two dose regimens of 250 μg/500 μg and 500 μg/1000 μg resulted in promising preliminary activity and a manageable safety profile in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. The phase 2 part of the trial is ongoing to further evaluate subcutaneous blinatumomab activity and duration of response."

Journal • P1/2 data • Retrospective data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Neutropenia • Oncology

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival (ASH 2025) - "Longer follow-up of chemotherapy-free treatment with InO and blina for older pts withnewly diagnosed, Ph-negative, CD22-positive, B-cell ALL reveals durable remissions and survival. TheA041703 regimen is a compelling option for first-line treatment of this pt population.Support: U10CA180821, U10CA18088; https://acknowledgments.alliancefound.org."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Breast Cancer • CNS Disorders • Hematological Malignancies • Hepatology • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Solid Tumor • CD22 • TP53 • ZNF384

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study. (ASH 2025) - "In conclusion, this study supports the use of blinatumomab consolidation in high-risk Ph-negative B-ALL patients. Building on these findings and to further refine risk-adapted treatmentstrategies, the ongoing GRAALL-2024 trial prospectively randomizes allo-HSCT in patients with pooroncogenic characteristics or EOI MRD response, but who achieve undetectable MRD after blinatumomab."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • IKZF1 • KMT2A

Redefining pediatric leukemia care - innovations in risk assessment and targeted treatment: a narrative review. (PubMed, Ann Med Surg (Lond)) - "Targeted therapies, such as tyrosine kinase inhibitors for Philadelphia chromosome-positive ALL, Chimeric Antigen Receptor T cell therapy for relapsed or refractory cases, and monoclonal antibodies like blinatumomab and inotuzumab ozogamicin, have transformed treatment outcomes while reducing chemotherapy-related toxicity. Despite these advances, challenges remain, including the development of therapy resistance (e.g., BCR-ABL1 and FLT3 mutations) and long-term adverse effects such as cardiotoxicity and secondary malignancies. This narrative review summarizes recent innovations in risk assessment and targeted therapies, highlights current challenges, and discusses future directions to optimize personalized pediatric leukemia care."

Journal • Review • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Cardiovascular • Hematological Malignancies • Leukemia • Oncology • Pediatrics • ABL1 • BCR • FLT3

Golden Gate Study: Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=304 | Recruiting | Sponsor: Amgen | Trial completion date: Sep 2031 ➔ Jul 2031

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial. (PubMed, Ann Hematol) - No abstract available

Journal • Minimal residual disease • P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Sep 2025 ➔ Jun 2026

Trial initiation date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. (PubMed, J Natl Compr Canc Netw) - "Although mAbs such as rituximab are primarily used in adults, the other modalities have demonstrated efficacy in both pediatric and adult patients with B-ALL. Among ADCs, inotuzumab ozogamicin (InO) has proven effective as monotherapy for relapsed disease, leading to FDA approval for patients aged >1 year with relapsed/refractory B-ALL...T-cell-engaging antibodies are now a standard component of therapy for most patients with newly diagnosed and relapsed B-ALL, following the successful integration of the bispecific T-cell-engager blinatumomab into chemotherapy regimens for both adults and children...Overall, immune-based therapies are now a mainstay of B-ALL therapy. This article reviews the efficacy and safety data of several immune-based therapies in B-ALL and discusses a number of outstanding questions and possible future directions for the use of immune-based approaches in the treatment of B-ALL."

Journal • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD22

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL. (PubMed, Blood Adv) - "Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for re-induction. Additional management of ALL subsets (T-ALL), CNS relapse, and the role of consolidation with allogeneic transplantation are addressed. Future research should evaluate these approaches with special attention to the unique AYA population and should evaluate quality of life outcomes."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation